Nanotechnology based therapeutics for lung disease.

Autor:	Doroudian M; Department of Medicine, Tallaght University Hospital, Dublin 24 & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland., MacLoughlin R; Aerogen, IDA Business Park, Galway, Ireland.; School of Pharmacy, Royal College of Surgeons, Dublin, Ireland.; School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland., Poynton F; Department of Medicine, Tallaght University Hospital, Dublin 24 & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland., Prina-Mello A; CRANN Institute and AMBER Centre, University of Dublin Trinity College, Dublin, Ireland.; Department of Medicine, Laboratory for Biological Characterization of Advanced Materials (LBCAM), Trinity College Dublin, Dublin, Ireland.; Nanomedicine Group, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Dublin, Ireland., Donnelly SC; Department of Medicine, Tallaght University Hospital, Dublin 24 & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland seamas.donnelly@tcd.ie.
Jazyk:	angličtina
Zdroj:	Thorax [Thorax] 2019 Oct; Vol. 74 (10), pp. 965-976. Date of Electronic Publication: 2019 Jul 08.
DOI:	10.1136/thoraxjnl-2019-213037
Abstrakt:	Nanomedicine is a multidisciplinary research field with an integration of traditional sciences such as chemistry, physics, biology and materials science. The application of nanomedicine for lung diseases as a relatively new area of interdisciplinary science has grown rapidly over the last 10 years. Promising research outcomes suggest that nanomedicine will revolutionise the practice of medicine, through the development of new approaches in therapeutic agent delivery, vaccine development and nanotechnology-based medical detections. Nano-based approaches in the diagnosis and treatment of lung diseases will, in the not too distant future, change the way we practise medicine. This review will focus on the current trends and developments in the clinical translation of nanomedicine for lung diseases, such as in the areas of lung cancer, cystic fibrosis, asthma, bacterial infections and COPD. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu